Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Immunotherapy was far more effective than targeted therapy in extending survival for people with certain kinds of advanced melanoma.
Tagrisso (osimertinib) was approved for non-small cell lung cancer patients with EGFR-positive tumors.
If your life depends on it, wouldn’t you want to know EVERYTHING that might help?
The survival improvement did not come at the cost of safety; the investigators saw no increase in serious side effects.
Precision medicine matches patients with the treatments most likely to work for them.
Osimertinib led to improved progression-free survival in people with common EGFR mutations.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.